Corrigendum to “A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival” (Leukemia Research (2021) 104, (S0145212621000564), (10.1016/j.leukres.2021.106555))

  • Jacqueline S. Garcia
  • , Ronan T. Swords
  • , Gail J. Roboz
  • , Meagan A. Jacoby
  • , Guillermo Garcia-Manero
  • , Wan Jen Hong
  • , Xiaoqing Yang
  • , Ying Zhou
  • , Uwe Platzbecker
  • , David P. Steensma
  • , Johannes E. Wolff
  • , Pierre Fenaux

Research output: Contribution to journal › Comment/debate

Fingerprint

Dive into the research topics of 'Corrigendum to “A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival” (Leukemia Research (2021) 104, (S0145212621000564), (10.1016/j.leukres.2021.106555))'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Nursing and Health Professions

Biochemistry, Genetics and Molecular Biology